Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases-Reference-Cited by-同舟云学术

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Published:2023-06 Issue: Volume:69 Page:451-468
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Lazaratos Anna-Maria,Maritan Sarah M.,Quaiattini Andrea,Darlix Amelie,Ratosa Ivica,Ferraro Emanuela,Griguolo Gaia,Guarneri Valentina,Pellerino Alessia,Hofer Silvia,Jacot William,Stemmler Hans-Joachim,van den Broek Marcel P.H.,Dobnikar Nika,Panet Francois,Lahijanian Zubin,Morikawa Aki,Seidman Andrew D.,Soffietti Riccardo,Panasci Lawrence,Petrecca Kevin,Rose April A.N.,Bouganim Nathaniel,Dankner Matthew^ORCID

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference38 articles.

1. The underlying biology and therapeutic vulnerabilities of leptomeningeal metastases in adult solid cancers;Dankner;Cancers,2021

2. A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer;Le Rhun;J Neuro Oncol,2013

3. HER2-positive breast cancer brain metastasis: a new and exciting landscape;Zimmer;Cancer Rep (Hoboken),2022

4. Evolving management of HER2+ breast cancer brain metastases and leptomeningeal disease;Mills;J Neuro Oncol,2022

5. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis;Bonneau;Eur J Cancer,2018

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Comprehensive Review of Current Treatment Modalities for Leptomeningeal Carcinomatosis in Breast Cancer;Critical Reviews in Oncology/Hematology;2024-09

2. Thérapies dans la méningite carcinomateuse du cancer du poumon, du sein et le mélanome : revue systématique de la littérature;Pratique Neurologique - FMC;2024-06

3. Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysis;Heliyon;2024-05

4. Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers;2024-03-24

5. An overview of the therapeutic strategies for neoplastic meningitis due to breast cancer: when and why?;Expert Review of Neurotherapeutics;2023-12-25